LCL161
Total Payments
$633,509
Transactions
12
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $48,477 | 1 | 0 |
| 2019 | $6,352 | 2 | 0 |
| 2018 | $154,376 | 4 | 0 |
| 2017 | $424,304 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $633,509 | 12 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| OTM A PHASE IB DOSE ESCALATION STUDY OF LCL161 IN COMBINATION WITH ORAL TOPOTECAN FOR PATIENTS WITH RELAPSED AND OR REFRACTORY SMALL CELL LUNG SCLC AND SELECT GYNECOLOGIC MALIGNANCIES | Novartis Pharmaceuticals Corporation | $306,350 | 0 |
| OPEN LABEL PHASE 2 SINGLE AGENT STUDY OF LCL161 IN PATIENTS WITH PRIMARY MYELOFIBROSIS PMF POST POLYCYTHEMIA VERA MYLEOFIBROSIS POST PV MF OR POST ESSENTIAL THROMBOCYTOSIS MYELOFIBROSIS POST ET MF | Novartis Pharmaceuticals Corporation | $280,000 | 0 |
| A PHASE IB MULTI CENTER OPEN LABEL DOSE ESCALATION STUDY OF WEEKLY ORAL LCL161 IN COMBINATION WITH INTRAVENOUS FIXED DOSE PACLITAXEL FOR THE TREATMENT OF ADVANCED SOLID TUMORS IN ADULT PATIENTS WHO ARE ELIGIBLE FOR TAXANE THERAPY | Novartis Pharmaceuticals Corporation | $25,732 | 0 |
| PHASE II STUDY OF LCL161 IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA WITH THE ADDITION OF CYCLOPHOSPHAMIDE FOR PROGRESSIVE DISEASE | Novartis Pharmaceuticals Corporation | $15,279 | 0 |
| A PHASE II MULTI CENTER OPEN LABEL NEOADJUVANT RANDOMIZED STUDY OF WEEKLY PACLITAXEL WITH OR WITHOUT LCL161 IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER | Novartis Pharmaceuticals Corporation | $6,148 | 0 |
Top Doctors Receiving Payments for LCL161
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $633,509 | 12 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $633,509
Product Information
- Type Drug
- Total Payments $633,509
- Total Doctors 0
- Transactions 12
About LCL161
LCL161 is a drug associated with $633,509 in payments to 0 healthcare providers, recorded across 12 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $48,477 was paid across 1 transactions to 0 doctors.
The most common payment nature for LCL161 is "Unspecified" ($633,509, 100.0% of total).
LCL161 is associated with 5 research studies, including "OTM A PHASE IB DOSE ESCALATION STUDY OF LCL161 IN COMBINATION WITH ORAL TOPOTECAN FOR PATIENTS WITH RELAPSED AND OR REFRACTORY SMALL CELL LUNG SCLC AND SELECT GYNECOLOGIC MALIGNANCIES" ($306,350).